{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:47:17Z","timestamp":1788562037305,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2024.10.026","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:10:32Z","timestamp":1731582632000},"page":"328.e17-328.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-660X","authenticated-orcid":false,"given":"Ellis","family":"Slotman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Richters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi P.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke J.","family":"Smilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette M.","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja K.H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja J.H.","family":"Raijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.urolonc.2024.10.026_bib0001","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.21037\/atm-20-2108","article-title":"An overview of patients with urothelial bladder cancer over the past two decades: a surveillance, epidemiology, and end results (SEER) study","volume":"8","author":"Zang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0002","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL). Survival by years after diagnosis, Relative Survival, Bladder, Stage IV. Accessed February 7, 2024.https:\/\/nkr-cijfers.iknl.nl\/viewer\/relatieve-overleving-per-jaren-na-diagnose?language=en_GB&viewerId=59bcb054-567d-46a0-8f64-3a75ec640b77."},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.026_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.10.026_bib0004","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0006","article-title":"Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience","volume":"27","author":"Swami","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0007","article-title":"Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study","volume":"25","author":"Richters","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0008","article-title":"Information provision to older patients receiving palliative chemotherapy: a quality study","author":"Lindhardt","year":"2021","journal-title":"BMJ Support Palliat Care"},{"issue":"7","key":"10.1016\/j.urolonc.2024.10.026_bib0009","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.2005.01.9208","article-title":"Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy","volume":"24","author":"Grunfeld","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.026_bib0010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1200\/JCO.2003.03.059","article-title":"Identifying potential indicators of the quality of end-of-life cancer care from administrative data","volume":"21","author":"Earle","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.026_bib0011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12913-016-1879-3","article-title":"Appropriate and inappropriate care in the last phase of life: an explorative study among patients and relatives","volume":"16","author":"Bolt","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"15","key":"10.1016\/j.urolonc.2024.10.026_bib0012","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archinternmed.2012.2364","article-title":"Factors important to patients' quality of life at the end of life","volume":"172","author":"Zhang","year":"2012","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.urolonc.2024.10.026_bib0013","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00520-023-08198-0","article-title":"Potentially inappropriate end-of-life care and its association with relatives' well-being: a systematic review","volume":"31","author":"Ham","year":"2023","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.026_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047256","article-title":"Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI","volume":"11","author":"Richters","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.026_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"11","key":"10.1016\/j.urolonc.2024.10.026_bib0016","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00345-021-03721-6","article-title":"The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis","volume":"39","author":"Shou","year":"2021","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.026_bib0017","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.10762","article-title":"Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I\/II trial with paclitaxel, cisplatin, and gemcitabine","volume":"95","author":"Bellmunt","year":"2002","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.urolonc.2024.10.026_bib0018","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0019","unstructured":"Centraal Bureau voor de Statistiek (CBS). Bevolking; geslacht, leeftijd en burgerlijke staat. Accessed January 19, 2024. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/7461bev\/table?ts=1705659221242<\/bib>"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.026_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/bjc.2012.186","article-title":"Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone","volume":"107","author":"Cavalli-Bj\u00f6rkman","year":"2012","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.026_bib0021","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/COC.0000000000000530","article-title":"Effects of social and contextual factors including marital status and children on the use of palliative chemotherapy in metastatic colorectal cancer","volume":"42","author":"Ahmed","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.026_bib0022","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3109\/0284186X.2012.758872","article-title":"Treatment decisions and discontinuation of palliative chemotherapy near the end-of-life, in relation to socioeconomic variables","volume":"52","author":"Rand\u00e9n","year":"2013","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.026_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001248","article-title":"Equal cancer treatment regardless of education level and family support? A qualitative study of oncologists\u2019 decision-making","volume":"2","author":"Cavalli-Bj\u00f6rkman","year":"2012","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.026_bib0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13012-020-00991-3","article-title":"Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature","volume":"15","author":"Bierbaum","year":"2020","journal-title":"Implement Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.026_bib0025","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00520-019-04875-1","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.026_bib0026","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2024.10.026_bib0027","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0028","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+ P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.10.026_bib0029","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2023.10.107","article-title":"LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial","volume":"34","author":"van der Heijden","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2024.10.026_bib0030","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(16)30378-3","article-title":"Differences in availability of cancer drugs across Europe","volume":"17","author":"Mayor","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924007051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924007051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T12:00:11Z","timestamp":1746878411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924007051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1078143924007051"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}